High immunocompetence in chronic hepatitis patients with normal alanine transaminase levels and and negative hepatitis B e‐antigen for the progression of liver fibrosis

Abstract

Abstract Introduction This study aimed to investigate the role of immunocompetence in chronic hepatitis B (CHB) patients with normal alanine transaminase (ALT) levels and negative hepatitis B e antigen (HBeAg) in the risk assessments of the progression of liver fibrosis. Methods We collected the clinical data of 57 patients with CHB, with normal ALT levels and negative HBeAg from December 2020 to December 2022. With hepatitis B virus (HBV) DNA > 20 IU/mL and ALT ≤ 40 U/L, these patients had never undergone antiviral therapy. The levels of CD4+, CD4+CD25+, CD8+, and CD4+CD25+CD127LOW regulatory T cells (Tregs) in the patients were detected using flow cytometry; the liver stiffness measurement (LSM) values of the patients were detected using Fibroscan. Results There was a statistically significant difference between the levels of fibrosis‐4 (FIB‐4) and hepatitis B surface antigen (HBsAg) when the cutoff point was HBsAg ≥ 1500 (p .05). Findings based on the analysis using logistic regression were as follows: (i) age was the independent risk factor when FIB‐4 was used as the indicator for assessing liver fibrosis; (ii) Treg was the independent risk factor when LSM was used as the indicator for assessing liver fibrosis. When Treg was used to predict liver fibrosis, the cutoff value, diagnostic efficacy, area under the receiver operating characteristic (ROC) curve, and p value of the ROC curve were 6.875, 0.641, 0.84, and .027, respectively. Conclusion Age and Treg are independent risk factors for progressive liver fibrosis. The cutoff value of Treg > 6.81 indicates the need for timely antiviral treatment and can serve as an indicator for evaluating liver fibrosis.

Keywords

• ALT
• CHB
• HBeAg‐negative
• progressive liver fibrosis
• Treg